Stockreport

Regeneron Pharmaceuticals: Q1 Beat Driven By Dupixent And Eylea HD Strength [Seeking Alpha]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF So, Eylea HD generated $468 million in U.S. sales for REGN, up 52.4% year-on-year. Moreover, in Q1, Regeneron's revenue from collaboration with Sanofi was about $1.61 [Read more]